What is the detailed daratumumab (Darzalex) plus bortezomib (Velcade) regimen for multiple myeloma, including treatment schedule, indications, side effects, and symptom management?

Daratumumab/Bortezomib (Darzalex/Velcade) Regimen for Multiple Myeloma

Daratumumab combined with bortezomib and dexamethasone (DVd) is a Category 1 preferred regimen for relapsed/refractory multiple myeloma after at least one prior therapy, with demonstrated superior progression-free survival (median 16.7 months vs 7.1 months) and overall response rates (82.9% vs 63.2%) compared to bortezomib/dexamethasone alone. 1, 2, 3

Indications

FDA-approved indications for DVd:

• Patients with relapsed/refractory multiple myeloma who have received at least one prior therapy 3
• Particularly effective in patients at first relapse, where median PFS reaches 27.0 months 2
• Can be used in both bortezomib-sensitive and bortezomib-naïve patients 1, 4

Clinical context where DVd is preferred:

• Lenalidomide-refractory disease (when patient has progressed on or after lenalidomide) 5, 6
• Patients who relapsed while on lenalidomide maintenance 6
• Frail or elderly patients who need effective therapy with manageable toxicity 6

Treatment Schedule

Dosing follows a 3-week cycle regimen 3:

Daratumumab Dosing

• Weeks 1-9: 16 mg/kg IV weekly (9 total doses)
• Weeks 10-24: 16 mg/kg IV every 3 weeks (5 doses)
• Week 25 onwards: 16 mg/kg IV every 4 weeks until disease progression

Bortezomib Dosing

• Standard: 1.3 mg/m² subcutaneously on days 1,4,8, and 11 of each 21-day cycle 7, 8
• Subcutaneous administration is preferred to reduce peripheral neuropathy risk 1, 4
• After 8 cycles in the pivotal trial, bortezomib was discontinued, but real-world data supports continuation as maintenance 9

Dexamethasone Dosing

• 20 mg IV or oral on daratumumab infusion days and bortezomib administration days 3, 8

Infusion Rates for Daratumumab

First infusion (Week 1):

• Start at 50 mL/hour for first hour
• Increase by 50 mL/hour increments every hour if tolerated
• Maximum rate: 200 mL/hour

Second infusion (Week 2):

• Start at 50 mL/hour
• Can increase to maximum 200 mL/hour

Subsequent infusions (Week 3 onwards):

• Can start at 100 mL/hour if no prior infusion reactions
• Maximum rate: 200 mL/hour 3

Side Effects and Toxicity Profile

Most Common Grade 3-4 Adverse Events

Hematologic toxicities:

• Thrombocytopenia: 45.3% (most common) 8, 2
• Neutropenia: 12.8% 8
• Anemia: 14.4% 8

Infusion-related reactions:

• Occur in 45.3% of patients 8
• 98.2% occur during first infusion only 8
• Mostly grade 1-2 (only 8.6% grade 3) 8
• Virtually absent after first infusion if proper premedication used

Infections:

• Grade 3-4 infections: 23% with daratumumab-containing regimens 4
• Upper respiratory tract infections more common 6

Peripheral neuropathy:

• Only 7% grade 2-3 peripheral neuropathy with weekly subcutaneous bortezomib 10
• Significantly lower than historical IV bortezomib rates
• Subcutaneous administration is mandatory to minimize this risk 1, 4

Symptom Management and Supportive Care

Pre-Infusion Medications (Mandatory)

To prevent infusion reactions:

• Corticosteroid: Dexamethasone 20 mg IV (serves dual purpose as anti-myeloma therapy)
• Antihistamine: Diphenhydramine 25-50 mg or equivalent
• Antipyretic: Acetaminophen 650-1000 mg 3

Post-Infusion Medications

• Corticosteroid: Consider oral dexamethasone 20 mg the day after first two infusions 3

Herpes Zoster Prophylaxis

Mandatory for all patients on proteasome inhibitors:

• Acyclovir 400 mg twice daily or valacyclovir 500 mg daily 1, 4
• Continue throughout bortezomib treatment

Thrombosis Prophylaxis

• Not typically required with DVd (unlike lenalidomide-containing regimens)
• Aspirin not routinely needed unless other risk factors present 1

Management of Specific Toxicities

Thrombocytopenia (most common):

• Monitor CBC weekly during first 3 cycles, then before each cycle
• Hold daratumumab if platelets <50,000/μL
• Reduce bortezomib dose by 25% if platelets 25,000-50,000/μL
• Platelet transfusions as needed for bleeding or platelets <10,000/μL

Neutropenia:

• G-CSF support (filgrastim or pegfilgrastim) for grade 3-4 neutropenia
• Consider prophylactic G-CSF in elderly or frail patients
• Hold treatment if ANC <1,000/μL with fever

Peripheral neuropathy prevention:

• Use subcutaneous bortezomib exclusively 1, 4
• Reduce bortezomib to once weekly if grade 2 neuropathy develops
• Discontinue bortezomib if grade 3-4 neuropathy occurs
• Consider switching to weekly dosing schedule preemptively in high-risk patients

Infusion reaction management:

• Interrupt infusion immediately if reaction occurs
• Administer additional antihistamines and corticosteroids
• Resume at 50% of rate once symptoms resolve
• Consider splitting first dose over 2 consecutive days (8 mg/kg each day) if severe reaction 3

Infection Prevention

• Antimicrobial prophylaxis: Consider fluoroquinolone prophylaxis during first 3 months
• Pneumocystis prophylaxis: Trimethoprim-sulfamethoxazole or alternative if CD4 count low or prolonged steroid use
• Monitor for respiratory infections closely given increased risk 4

Treatment Duration and Monitoring

Continue treatment until disease progression or unacceptable toxicity 3, 8

• Real-world data shows median PFS of 16-21.8 months 9, 10
• Continuous therapy provides ongoing disease control
• No arbitrary stopping point based on number of cycles

Response assessment schedule:

• Every 3 cycles (approximately every 9 weeks) during intensive phase
• Every 3-4 months during maintenance phase
• Use serum/urine protein electrophoresis and free light chains
• Consider bone marrow biopsy for complete response confirmation

Important Clinical Caveats

Blood bank interference:

• Daratumumab causes false-positive indirect Coombs test 1
• Type and screen must be completed before first daratumumab dose 3
• Inform blood bank of daratumumab use for future transfusions

High-risk cytogenetics:

• Patients with del(17p), t(4;14), or extramedullary disease have inferior outcomes with DVd 10
• Consider alternative regimens (CAR T-cell therapy, belantamab-based regimens) in these patients 11

Early relapse patients:

• Those relapsing within 18 months of initial treatment or within 12 months of transplant have worse outcomes 10
• May require more aggressive approaches or clinical trial enrollment

Dose modifications:

• Weekly bortezomib schedule reduces neuropathy without compromising efficacy 10
• Daratumumab dose reductions are not recommended; hold for toxicity and resume at full dose

Real-world effectiveness:

• Actual clinical practice shows 82% ORR and 16-month median PFS at first relapse 10
• Results comparable regardless of prior lenalidomide exposure 10
• Continuous bortezomib maintenance after 8 cycles shows promising results (median PFS 21.8 months) 9